Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
J Infect Dis. 2020 May 11;221(Suppl 4):S460-S470. doi: 10.1093/infdis/jiz564.
The error-prone nature of RNA-dependent RNA polymerases drives the diversity of RNA virus populations. Arising within this diversity is a subset of defective viral genomes that retain replication competency, termed defective interfering (DI) genomes. These defects are caused by aberrant viral polymerase reinitiation on the same viral RNA template (deletion DI species) or the nascent RNA strand (copyback DI species). DI genomes have previously been shown to alter the dynamics of a viral population by interfering with normal virus replication and/or by stimulating the innate immune response. In this study, we investigated the ability of artificially produced DI genomes to inhibit Nipah virus (NiV), a highly pathogenic biosafety level 4 paramyxovirus. High multiplicity of infection passaging of both NiV clinical isolates and recombinant NiV in Vero cells generated an extensive DI population from which individual DIs were identified using next-generation sequencing techniques. Assays were established to generate and purify both naturally occurring and in silico-designed DIs as fully encapsidated, infectious virus-like particles termed defective interfering particles (DIPs). We demonstrate that several of these NiV DIP candidates reduced NiV titers by up to 4 logs in vitro. These data represent a proof-of-principle that a therapeutic application of DIPs to combat NiV infections may be an alternative source of antiviral control for this disease.
RNA 依赖的 RNA 聚合酶的易错性质驱动了 RNA 病毒群体的多样性。在这种多样性中出现了一小部分保留复制能力的缺陷病毒基因组,称为缺陷干扰(DI)基因组。这些缺陷是由异常的病毒聚合酶在同一病毒 RNA 模板(缺失 DI 物种)或新生 RNA 链(回文 DI 物种)上重新起始引起的。先前已经表明,DI 基因组通过干扰正常病毒复制和/或刺激先天免疫反应来改变病毒群体的动态。在这项研究中,我们研究了人工产生的 DI 基因组抑制尼帕病毒(NiV)的能力,尼帕病毒是一种高致病性的生物安全 4 级副粘病毒。在 Vero 细胞中,通过高多重感染传代 NiV 的临床分离株和重组 NiV,从其中鉴定出了个体 DI,使用下一代测序技术。建立了测定法来生成和纯化天然存在的和计算机设计的 DI,作为完全包裹的、传染性的病毒样颗粒,称为缺陷干扰颗粒(DIP)。我们证明,这些 NiV DIP 候选物中的几种在体外将 NiV 滴度降低了多达 4 个对数。这些数据代表了一个原理证明,即 DIP 作为治疗性应用来对抗 NiV 感染可能是该疾病抗病毒控制的另一种来源。